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Abstract Linear scleroderma en coup the sabre (LSCS),
progressive facial hemiatrophy (PFH) and autoimmune
encephalitis are distinct clinical entities, although patients
with overlapping features have been reported. We per-
formed a multicenter retrospective review of a series of
children with LSCS and/or PFH to explore the relation
between these entities. The files of 16 children were
reviewed, 11 presented with LSCS, 5 with PFH, with time
overlapping cutaneous features were seen. Extracutaneous
signs were found in both groups. ANA were present in
more than 50 % of patients. Almost half of our patients
presented with CNS manifestations comprising unilateral
headache, migraine and epilepsy with or without abnor-
malities on MRI. Brain biopsy in one patient was consis-
tent with Rasmussen encephalitis. In two other children,
associated autoimmune manifestations were present.
Conclusion: Our patient cohort brings more arguments to
consider LSCS and PFH as a single disease entity with LSCS
and superficial skin involvement at one end of the spectrum
and PFH with involvement of subcutaneous deep tissue at the
other end. In both entities, encephalitis can be observed. Our
findings of circulating ANA, intradermal lymphocytes and
IgG, intrathecal IgG production and clinical improvement
with immunosuppressive therapy endorse the concept of a
possible common immune-inflammatory pathogenesis.
What is known:
• LSCS, PFH and immune-inflammatory encephalitis are distinct clinical
entities, but patients with overlapping features have been reported.
What is new:
• We present a unique paediatric cohort with LSCS, PFH and/or
encephalitis.
• We endorse the concept of a common immune-inflammatory disease
process.
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Introduction
Linear scleroderma is the most frequent form of localized
scleroderma in children, involving 65 % of patients in a large
multicenter series [22]. The incidence in the general popula-
tion is rare and estimated to 1 per 100,000. Involvement of the
frontoparietal area is known as Ben coup de sabre^ (LSCS).
The onset of this condition is mostly during late childhood,
and stabilization occurs after several years. LSCS usually pre-
sents as a localized area of erythema or waxy induration with a
surrounding halo of erythema. With time, the centre becomes
shiny, ivory whitish and more infiltrated. It often leaves a
hyperpigmented depressed scar. Lesions may extend to the
scalp, where they cause alopecia, or to the nose, cheek, chin
and neck. Atrophy of the affected side of the face is possible
and usually develops within 1 year after onset. LSCS can
occasionally be associated with central nervous system or
ophthalmologic symptoms such as anterior uveitis,
episcleritis, acquired glaucoma, xerophtalmia and keratitis
[21].
Progressive facial hemiatrophy (PFH) or Parry-Romberg
syndrome is a very rare condition that presents with severe
atrophy of the soft tissues (without epidermal involvement)
usually starting on the cheek, later extending to the forehead
and scalp, sometimes resulting in alopecia, and to the chin or
even the neck. The first signs usually appear in the first or
second decade of life and a spontaneous stabilization occurs
after 3–10 years, often with serious esthetical and neurological
sequelae. Sclerosis of the skin is absent or less prominent than
in linear scleroderma. The underlying bone and muscles may
become atrophic leading to malocclusion of the jaws, teeth
defects and asymmetric tongue. Central nervous system and
ophthalmological complications are frequent [15, 21].
The hypothesis that LSCS and PFH are variants of the
same disease process is a long-standing controversy [10, 15,
18]. Moreover, overlap between these diseases and
encephalitis has been reported [1, 13, 14]. The pathogenesis
of these diseases remains a matter of discussion [15, 18].
With the present cohort study, we postulate to provide more
arguments to the concept of an immune-inflammatory spec-
trum of disease that comprises these entities.
Patients and methods
The clinical records, imaging data and laboratory investiga-
tions of all children, diagnosed with LSCS or PFH, seen at the
paediatric rheumatology, neurology or dermatology consulta-
tions of the Leuven University Hospital, Belgium, Centre
Hospitalier Luxembourg and the Leiden University Center,
the Netherlands, between 1988 and 2012 were reviewed.
A consent was obtained according to the Declaration of
Helsinki; the study has been performed conforming the stan-
dards currently applied in Belgium, The Netherlands and Lux-
embourg. Photographs of patients were published with con-
sent of the respective patients.
Results
After reviewing the medical files, 16 patients were included in
this study. The clinical findings, laboratory results and imag-
ing data are summarized in Table 1.
Eleven (11/16) patients presented with LSCS with a medi-
an age at presentation of 5 years (range 3–12 years). Five of
these were male, 6 were female. Four of these patients devel-
oped atrophy of the hemiface, mostly within 1 to 2 years after
appearance of the first signs of the initial lesion. The other five
children (5/11) presented with PFH with a median age at pre-
sentation of 4.8 years (range 3–9, 5 years). The male/female
ratio was 2:3. Most of them (3/5) had localized scleroderma
lesions as well (Fig. 1). At the end of the observation period,
nine of our patients (9/16) had obvious hemifacial atrophy.
In none of these children, there was a history of trauma or
infection preceding the onset of the skin lesions.
Extracutaneous signs were found in 7 of the 11 patients
with LSCS and in 4 of the 5 with PFH. Intra-oral lesions with
asymmetry of teeth arches and missing teeth were present in 3
patients. Ophthalmologic abnormalities included ptosis of
eyelid, enophthalmia, bilateral anterior uveitis and papillary
asymmetry. CNS manifestations ranged from hemicranial
headache over migraine to epilepsy and Rasmussen encepha-
litis. The 2 patients with seizures developed this complication,
respectively, 7 years (patient 6) and 6 years (patient 12) after
the first signs of scleroderma or atrophy. Patient 6, who was
diagnosed with LSCS at the left frontal area, presented with
complex partial seizures in addition to complaints of
hemicranial headache. Further investigations showed positive
ANA not only in the serum but also in the CSF of this patient.
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Initially, T2-hyperintense signals were seen on MRI in the
white matter of the left parieto-occipital region, temporal and
occipital region, the site of her LSCS lesion. Single photon
emission computed tomography (SPECT) showed hypoperfu-
sion in the temporoparietal region. She was treated with
valproic acid and methotrexate. Her epilepsy was well con-
trolled. After several years, lesions were less pronounced on
MRI and SPECT perfusion images normalized (Fig. 1f). Pa-
tient 12, diagnosed with PFH, suffered from severe and pro-
gressive complex partial seizures becoming more generalized
and continuous with time. They were associated with postictal
hemiparesis and severe cognitive disturbances. MRI showed a
T2-hyperintense signal in the left subcortical parietal area,
corresponding to the site of her PRS and coinciding with a
region of hypoperfusion on SPECT (Fig. 1g, h). With time,
she developed new lesions on the left hemisphere and in the
right parietal and frontal subcortical and cortical area. Brain
biopsy showed an inflammatory infiltrate with neuronal dam-
age consistent with Rasmussen encephalitis. Her epilepsy
remained refractory to multiple anti-epileptic drugs and
hemispherotomy. In the other 5 patients in whom MRI was
performed, including 2 children with severe migraine, no ab-
normalities were found in 4 of them, except in patient 14 were
T2-hyperintense signals were found in a child with a develop-
mental delay. In patient 9, CT showed 2 ipsilateral nodular
lesions in the temporal lobe and nucleus caudatus.
Two of our patients had polyarthritis (patients 10 and 13,
diagnosed with PFH), mainly of the small joints. In one pa-
tient, wrist tenosynovitis was associated with a severe carpal
tunnel syndrome.
Additional autoimmune features comprised uveitis and ce-
liac disease in patient 10.
Of the 16 patients included, 8 patients were diagnosed be-
fore and 8 after the year 2000. There seemed to be no differ-
ence in age of onset of the disease and in both subpopulations;
extracutaneous symptoms were equally present.
Laboratory tests showed presence of autoimmunity in the
form of positive ANA in three out of nine LSCS patients and
in two out of five patients with PFH. Only titers >1/80 were
considered to be relevant. In patient 6, ANAwere found both
in the serum and the CSF. In patient 12, an intrathecal IgG
production was suggested/proven by the presence of nine
oligoclonal IgG bands in the CSF without corresponding
bands in the serum. During follow-up, additional analysis
showed positive anti-NMDA receptor antibodies in the serum.
A skin biopsy performed in the region with hemiatrophy
but without clinically visible sclerosis in patient 11 (with PFH)
showed histopathological signs of fibrosis associated with a
lymphocytic perivascular infiltrate and IgG and IgM deposits.
Children with only skin lesions received either topical ste-
roids and calcipotriol or no treatment (if the lesions were sta-
ble). Patients 5, 6, 7, 10, 12, 14 and 15 were treated system-
atically with methotrexate with or without corticosteroids. InT
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patient 5, 6, 10, 14 and 15, this resulted in a remission of the
clinical signs. In patient 7, the progression of the hemiatrophy
could not be stopped. In patient 12, skin lesions stabilized, but
neurologically, she deteriorated further (as described earlier).
Discussion
We present a large paediatric patient cohort of 16 childrenwith
LSCS and/or PFH, associated with autoimmunity and/or en-
cephalitis. The clinical signs and onset of presentation were
not different from what is known in literature for these condi-
tions. Extracutaneousmanifestations included dental, ophthal-
mological, autoimmune and neurological abnormalities. Our
findings illustrate a wide clinical spectrum of these entities
with significant overlap.
Our patient cohort corroborate the hypothesis that LSCS
and PFH are similar clinical entities with LSCS and superficial
skin involvement at one end of the spectrum and PFH with
involvement of subcutaneous deep tissue at the other end, as
suggested previously by Lehman et al. [10].
All patients had localized scleroderma lesions, nine of
them had associated hemifacial atrophy. Four patients had
been diagnosed with LSCS before atrophy of the ipsilat-
eral face became apparent, which is in agreement with the
findings of Tollefson [18]. In our cohort, most PFH pa-
tients had a small or larger lesion of localized scleroderma
in the face. In one of our patients, the discrete scleroder-
ma lesion had disappeared when his hemifacial atrophy
was fully developed. The skin biopsy in our patient with
clinical PFH showed histological signs typical for LSCS:
fibrosis associated with a lymphocytic perivascular infil-
trate and IgG and IgM deposits [9].
A B1 B2
EDC
Before treatment
After treatment
F G H
Fig. 1 Clinical pictures and imaging of some patients. a Patient 6: LSCS
started at the age of 5. Lesions are present on the left forehead and frontal
scalp with hair loss. b Patient 7: LSCS of the right forehead started at the
age of 6 (1), at the age of 8 PFH of the right hemiface appeared (2). c
Patient 10: 10-year-old girl with right hemifacial atrophy with morphea
lesions of the right cheek and neck. d Patient 11: before PFH started, this
boy had a small morphea lesion on his right forehead. Moreover, he had
alopecia of the right frontotemporal area. e Patient 13: girl with PFH of
the left side. She developed a small patch of morphea of the chin, hypo-
plasia of the maxillar bone and teeth anomalies. f Patient 6: LSCS patient
with complex partial seizures. Initial hypoperfusion in the temperoparietal
region on SPECT disappeared after treatment with MTX. g, h MRI and
SPECT of patient 12: area of hypoperfusion on SPECT (h) corresponds
with hyperintense areas on T2 of MRI (g)
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The spectrum of extracutaneous manifestations is similar
for LSCS and PFH, but they seem to bemore frequent in PFH.
We observed dental complications in 3, ophthalmological in 4
and neurological complications in 9 of our patients. We also
found the association with other autoimmune diseases
(polyarthritis, celiac disease) in 2 of the 16 patients (1 with
LSCS, 1 with the combination of LSCS and PFH). These
findings are in agreement with a multicenter study by Zulian
et al. in which neurological and ophthalmological complica-
tions were the most common extracutaneous manifestations in
LSCS and PFH [21]. The most common ophthalmic manifes-
tation of PFH and LSCS is progressive enophthalmia [6, 19],
explained by atrophy of the orbital fat. The most common
neurological complications are seizures and migraine, which
may even be the presenting signs [16]. Most neurological
problems are ipsilateral to the cutaneous signs (as in patient
6, 7, 8, 14); contralateral lesions have been described as well
as generalized lesions, as in our patient 12 [18].
The pathogenesis of both LSCS and PFH is incompletely
understood. Various proposed etiologies include trauma, in-
fection, a disturbance of fat metabolism, a cranial vascular
malformation or sympathic dysfunction [5]. More recently,
an autoimmune aetiology has been proposed. By studying
cytokine profiles in serum and skin biopsy specimens of
scleroderma patients, Th1-responses seem to play an impor-
tant role in the active state of the disease, whereas Th2-
responses are more important in fibrosis extent and disease
damage. Th17-cells may be instrumental in the transition be-
tween these two phases as they can modulate the propagation
of inflammation and the transition to the fibrotic state of the
disease [9].
The neurological findings in two of our patients may
strengthen the hypothesis of an autoimmune background for
these two conditions. Autoimmune encephalitis is character-
ized by the presence of various autoantibodies both in serum
and CSF of the affected individuals [13, 14]. In the two pa-
tients with the most severe neurological complications, addi-
tional autoimmune manifestations in the CSF were found:
ANA in the CSF in one and signs of intrathecal IgG produc-
tion with—several years after the initial presentation—the
presence of anti-NMDA antibodies in the other. In the latter,
the brain biopsy previously showed an inflammatory infiltrate
with neuronal damage consistent with Rasmussen encephali-
tis. It is known that on immunofluorescent staining on biopsy
specimens of Rasmussen patients, most of the infiltrating cells
are T lymphocytes causing apoptotic death of neurons and
astrocytes, but not of oligodendrocytes or myelin. Additional
spectratyping revealed the clonal expansion of a subset of
CD8+ T cells. Further, an accumulation of immunoglobulins
and of C3 and C1q within the vessel wall can be found [2, 7].
In Rasmussen encephalitis, MRI findings evolve with
time. Initial imaging studies can be normal. The early
stages are characterized with hyperintense signalling on
T2 and FLAIR images in cortex and white matter,
which seem to correlate well with the higher number
of T cells and reactive astrocytes on histopathology (as
was found in patient 12) [3]. Serial MRIs during the
disease course can demonstrate progression, worsening
of the hyperintense signalling and atrophy.
In cases of Parry-Romberg, white matter high signal inten-
sity on MRI is a common neuroimaging finding. These white
matter changes are considered as a slowly progressive inflam-
matory process, comparable with the pathophysiologic mech-
anisms of Ramussen’s encephalitis [17].
Other cases of overlap between PFH and Rasmussen en-
cephalitis have been reported [13, 14].
Inial work up:
Clinical assessment: linear scleroderma lesions general
Lab: complete blood cell count, ANA, liver & kidney funcon
Ophtalmological evaluaon
Brain MRI with tesng for neuronal surface abs if abnormal
During follow-up:
Clinical assessment: signs of acve local disease. New 
autoimmune manifestaons (extracutaneous involvement)
Lab for  monitoring drug safety (complete bloof cell count, 
liver & kidney funcon)
Ophtalmological evaluaon once yearly
Brain MRI if symptoms suggesve of neurological
involvement
Topical calcitriol ± corcosteroids
With/without
Systemic treatment
Methrotrexate
1mg/kg/week PO/SC
max 25 mg for 1 year
Methrotrexate 1mg/kg/week
PO/SC
max 25 mg for 1 year
Prednisone  2 mg/kg/day, max 
60 mg/d
Taper:
Week 8: 50%
Week 16: 25%
Week 24: 12,5 %
Week 48: off corcosteroids
Methrotrexate 1mg/kg/week
PO/SC
max 25 mg for 1 year
Methylprednisolone 30 mg/kg 
per dosis, max 1 g
- + 
-
-
-
-
-
-
-
+
-
-
-
-
+
* 3 consecuve days per 
month for 3 months
OR
* 1 dose/week for 12 weeks
No Taper
Linear scleroderma en coup de sabre/ progressive facial hemiatrophy
Fig. 2 Flow pathway illustrating proposed investigative (left) and management strategies (right) (according to Li et al. [11]). Decision to treat and choice
of plan is based on physician judgment of best care. PO per os, SC subcutaneous
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Finally with immunosuppressive therapy (methotrexate
and corticosteroids), an arrest of disease progression and sta-
bilization of MRI findings could be obtained in some patients
of our cohort.
There are at present no evidence-based guidelines
about the optimal follow-up and treatment for LSCS and
PFH, as no large randomized studies are available. Many
authors’ advices to perform MRI in all patients with both
LSCS and PFH as neurological complications are not sel-
dom. Early signs may be detected by MRI [4] or even
earlier by SPECT [12] before they become clinically rel-
evant. How often MRI should be repeated and how long
remain a matter of debate. Abnormalities on MRI or EEG
have been described in patients without clinical neurolog-
ical symptoms [18, 21], the significance over time is
therefore uncertain. In patients with MRI/EEG abnormal-
ities, we would recommend a systematic search for known
autoantibodies to neuronal (surface) antigens (Fig. 2).
Most treatment options are based on immunosuppression.
For localized scleroderma, a randomized therapeutic trial did
demonstrate a beneficial effect of methotrexate in association
with systemic steroids [20], but the efficacy of this combina-
tion in PFH has not been convincingly demonstrated. Some
case reports suggest a positive effect of immunosuppressive
therapy for PFH [8], but in other patients, those therapies did
not prove to be helpful. Our cases treated with systemic cor-
ticosteroids and methotrexate seem to confirm those observa-
tions. For the patients treated in our institution from the time of
diagnosis, we used a combination of steroids and methotrex-
ate, as well as topical calcitriol, according to the guidelines
published for juvenile localized scleroderma [11] (Fig. 2).
There is a clear need for a large prospective study in this
group of patients to determine the risk factors for development
of extracutaneous manifestations, adequate surveillance and
therapy. A prospective study of natural history, immune-
inflammatory characteristics and gene expression profile in a
larger group of patients is essential to advance our understand-
ing of disease course and pathogenesis, and to guide the de-
velopment of adequate therapies.
Conclusion
Paediatricians taking care of children with LSCS and/or PFH
should be aware of potential neurological involvement and
other autoimmune manifestations. International collaborative
efforts to study the natural history of this disease entity and to
increase our understanding of an underlying immune-
inflammatory pathogenesis may help develop more effective
therapies.
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